Skip to content

Design and Clinical Application of innovative laryngeal mask for painless fiberoptic bronchoscope

Design and Clinical Application of New Endoscopic Laryngeal mask

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044849
Enrollment
Unknown
Registered
2021-03-30
Start date
2021-03-31
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung desease

Interventions

Group A:Innovative laryngeal mask for painless fiberoptic bronchoscope

Sponsors

Department of Anesthesiology, the First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 65 years, regardless of gender; 2.ASA is classified as I-III; 3.18 kg/m^2= 93%; SBP >= 90mmHg DBP >= 55mmHg 50 beats /min <= heart rate <=100 beats/min; 6.Be able to understand and voluntarily sign the informed consent form (ICF), and be willing to abide by and expect to complete the test according to the requirements of the test plan.

Exclusion criteria

Exclusion criteria: 1.Those who have contraindications of deep sedation/general anesthesia or have had a history of sedation/anesthesia accidents in the past; 2.Allergic or taboo to benzodiazepines, opioids, propofol, Masini, naloxone, lidocaine and other drugs and their pharmaceutical components; 3.Those who have undergone endotracheal intubation and/or mechanical ventilation before bronchoscopy; 4.The screening period/baseline period has the following medical history: (1)History of cardiovascular system: 1)Uncontrolled or poorly controlled blood pressure [SBP >= 170 mmHg and/or DBP >= 105 mmHg without antihypertensive treatment, or SBP>160mmHg and/or DBP > 100 mmHg after antihypertensive treatment]; 2)Aneurysm; Heart failure (NYHA grade III-IV); Severe superior vena cava obstruction syndrome; Severe arrhythmia (such as third-degree atrioventricular block, Adams-stokes syndrome, etc.); Unstable angina pectoris; Myocardial infarction occurred within 6 months before screening; Heart rate of resting electrocardiogram = 1.5 x ULN; (4)The time of activating partial thromboplastin >= 1.5 x ULN; (5)Glutamic pyruvic transaminase and/or glutamic oxaloacetic transaminase >= 3 x ULN; (6)Total bilirubin >= 1.5 x ULN; (7)Serum creatinine >= 1.5 x ULN. 6.The modified Markov score is Grade III or above; 7.There is a history of drug abuse, drug abuse, alcoholism and long-term use of psychotropic drugs within 2 years before the start of the screening period. Alcoholism is defined as regular drinking more than 14 times a week (once = 150 mL wine or 360 mL Beer or 45 mL spirits); 8.Pregnant or lactating women; 9.Fertility women or men are unwilling to use contraception during the whole study period; Or subjects who have a pregnancy plan within 3 months after the end of the study (including male subjects); 10.Those who participated in any clinical trials (including clinical trials of drugs or devices) as subjects within 1 month before being selected; 11.Other circumstances judged by the researcher as unsuitable for selection.

Design outcomes

Primary

MeasureTime frame
minimum pulse oxygen saturation;

Secondary

MeasureTime frame
bronchoscope time;anesthesia recovery time;satisfaction of endoscope doctor;blood pressure;heart rate;pulse oxygen saturation;

Countries

China

Contacts

Public ContactXia Min

Department of Anesthesiology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

dannyxiamin1982@sina.com+86 15155123101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026